PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas

Inclusion Criteria: * 1 At the age of 18\~75, regardless the gender * 2 The lesion of primary surgery was diagnosed as WHO II\~IV Glioma by histologic pathology * 3 Received radiotherapy and Temozolomide-based chemotherapy within 5 years * 4 Recurrent and respectable gliomas, and have been neurosurgically resected * 5 The resected recurrent gliomas was identified as WHO III\~IV Glioma by histologic pathology * 6 None postoperative standard therapeutic regimens can be followed when participating the recruitment * 7 Can understand the trial's content and sign informed consent Exclusion Criteria: * 1 Having other untreated malignant tumors * 2 The amount of resected tumors is not enough for genomic sequencing or PTCs drug screening * 3 Received Carmustine implants within 6 months prior to enrollment * 4 Subjects with active HBC, HCV or HIV infection * 5 Subjects with uncontrolled cardio- or cerebro- vascular diseases * 6 Subjects with uncontrolled psychiatric diseases or condition that could increase adverse events or interfere the evaluation of outcomes * 7 Subjects with other conditions in their active phase that would interfere trial participation * 8 Subjects receiving immunosuppressants after organ transplantation * 9 Subjects with unstable pulmonary embolism, deep venous embolism, or other major arterial and venous thromboembolic events that occur within 30 days before the enrollment, or receiving anticoagulant therapy * 10 Subjects in pregnancy or breastfeeding, or those who plan to become pregnant during treatment or within 2 months after the end of treatment * 11 Subjects with other conditions that would interfere participating in the trial at the investigator's discretion * 12 Subjects with medical conditions that affect signing the written informed consent or complying with the research procedures; or patients who are unwilling or unable to comply with the research procedures